Oct. 10 (UPI) --Teva Pharmaceuticals, the largest generic drug manufacturer in the United States, has agreed to pay $450 million to resolve two claims that allege the company violated the Anti ...

Under the settlement and license agreement, Neos has granted Teva the right to manufacture and market its generic version of Cotempla XR-ODT extended-release orally disintegrating tablets in the ...

The FDA has approved Teva’s Huntington’s Disease drug, the first new treatment for the neurological disease in almost a decade. The FDA has approved Austedo (deutetrabenazine) tablets for the ...

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating ...